Human CD34⁺-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8⁺ T cell and NK cell responses in vitro and in vivo.

ABSTRACT: Allogeneic stem cell transplantation (alloSCT) can be curative for hemato-oncology patients due to effective graft-versus-tumor immunity. However, relapse remains the major cause of treatment failure, emphasizing the need for adjuvant immunotherapies. In this regard, post-transplantation dendritic cell (DC) vaccination is a highly interesting strategy to boost graft-versus-tumor responses. Previously, we developed a clinically applicable protocol for simultaneous large-scale generation of end-stage blood DC subsets from donor-derived CD34⁺ stem cells, including conventional type 1 and 2 DCs (cDC1s and cDC2s), and plasmacytoid DCs (pDCs). In addition, the total cultured end-product (DC-complete vaccine), also contains non-end-stage-DCs (i.e. non-DCs). In this study, we aimed to d

SUBMITTER: van Eck van der Sluijs J 

PROVIDER: S-EPMC10511603 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature